肝癌晚期采用靶向药和pd1治疗，能活多长时间？

问：肝癌晚期采用靶向药和pd1治疗，能活多长时间？

看下面，目前的肝细胞肝癌的一线治疗贝伐珠单抗联合阿特利珠单抗，最好的数据，中位总生存期是19.2月，也就是一年半多一些。

Atezolizumab plus bevacizumab demonstrated statistically significant and clinically meaningful improvements in OS vs sorafenib (HR, 0.58 [95% CI, 0.42-0.79]; P <0.001), and progression-free survival (PFS; HR, 0.59 [95% CI, 0.47-0.76]; P <0.001). In 501 patients followed for a median of 15.6 months, the median OS was 19.2 month with atezolizumab plus bevacizumab vs 13.4 months with sorafenib. The median PFS was 6.8 months with atezolizumab plus bevacizumab vs 4.3 months with sorafenib.

现在的大医院，主治医生对肝癌晚期患者一般都是采用靶向药和pd1治疗，请问采用这种治疗方式的晚期肝癌患者一般生存期有多长时间？

优秀作者:中医传承膏方